Scisparc Ltd (SPRC)

$0.53 +0.00 (0.63%)
Market Cap 1.88M
Revenue (ttm) 1.31M
Net Income (ttm) -6.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -479.39%
Debt to Equity Ratio -30.38
Volume 80,200
Avg Vol 1,203,544
Day's Range N/A - N/A
Shares Out 3.58M
Stochastic %K 11%
Beta 1.72
Analysts Strong Buy
Price Target $20.00

Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially man...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 334 47180
Address:
Tower A, 2nd Floor 20 Raul Wallenberg Street, Tel Aviv, Israel
BillionerOfKing
BillionerOfKing Feb. 23 at 7:07 PM
$SPRC Current Stock Price: $0.53
0 · Reply
LetsWinSD
LetsWinSD Feb. 20 at 7:53 PM
$SPRC not surprised if they do another R/S. Best stock to short. Down 3 - 10% everyday.
0 · Reply
DARKDREAMER
DARKDREAMER Feb. 20 at 7:25 PM
$SPRC I’m watching you
0 · Reply
LetsWinSD
LetsWinSD Feb. 20 at 6:44 PM
$SPRC a constant lower lows. A step down to 0 and delist already. What a POS! Only 2 employees at #SPRC, what a total scam! A bunch of bullshit PR's of patent this and patent that but no actual products.
0 · Reply
LetsWinSD
LetsWinSD Feb. 19 at 6:08 PM
$SPRC TRASH!!! They have been silent and letting retailers bleed.
0 · Reply
LetsWinSD
LetsWinSD Feb. 18 at 11:42 PM
$SPRC your money will dwindle away if you invest in this. A COMPLETE SCAM COMPANY with no real product and BS PR.
0 · Reply
looking4financialfreedom
looking4financialfreedom Feb. 18 at 2:23 AM
$SPRC come on!!!!! Let’s wake up to this ASK price!!!! This would the biggest, most epic turn around of all time! (For me at least) #shortsqueeze
1 · Reply
MovingFast77
MovingFast77 Feb. 17 at 8:58 PM
$SMX AH run . $SMX and $SPRC both #LOWFLOAT ready for a #shortsqueeze
0 · Reply
MAK98TRADER
MAK98TRADER Feb. 17 at 6:52 PM
$SPRC between how the markets been and the stock itself only a really good PR can save this at this point in time oversold technicals are not playing a role here
0 · Reply
LetsWinSD
LetsWinSD Feb. 17 at 6:51 PM
$SPRC A POS! TRASH! SCAM!
0 · Reply
Latest News on SPRC
SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Feb 2, 2026, 8:24 AM EST - 21 days ago

SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Feb 2, 2026, 8:00 AM EST - 21 days ago

Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization

Jan 26, 2026, 8:13 AM EST - 4 weeks ago

SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization

SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity

Jan 13, 2026, 6:55 AM EST - 5 weeks ago

SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity

SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Jan 12, 2026, 4:02 PM EST - 6 weeks ago

SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Neurothera Labs Announces Results of AGM

Jan 8, 2026, 6:00 PM EST - 6 weeks ago

Neurothera Labs Announces Results of AGM

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Dec 30, 2025, 8:17 AM EST - 7 weeks ago

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Dec 30, 2025, 8:00 AM EST - 7 weeks ago

Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Dec 2, 2025, 9:29 AM EST - 2 months ago

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Dec 2, 2025, 8:05 AM EST - 2 months ago

Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio

Dec 1, 2025, 8:32 AM EST - 3 months ago

SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio

SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems

Nov 26, 2025, 7:38 AM EST - 3 months ago

SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 20, 2025, 6:42 AM EST - 3 months ago

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 19, 2025, 8:30 AM EST - 3 months ago

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

CMND

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

Oct 24, 2025, 7:55 AM EDT - 4 months ago

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Oct 23, 2025, 4:03 PM EDT - 4 months ago

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

Oct 23, 2025, 8:55 AM EDT - 4 months ago

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

Scisparc Ltd. - Early Warning Regarding Acquisition Of Common Shares Of Neurothera Labs Inc.

Oct 22, 2025, 3:30 PM EDT - 4 months ago

Scisparc Ltd. - Early Warning Regarding Acquisition Of Common Shares Of Neurothera Labs Inc.

SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Oct 20, 2025, 7:41 AM EDT - 4 months ago

SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

Oct 15, 2025, 7:05 AM EDT - 4 months ago

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors

Oct 6, 2025, 6:40 AM EDT - 5 months ago

SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Sep 29, 2025, 4:03 PM EDT - 5 months ago

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

SciSparc Stock Surges As It Launches Initiative To Advance Drug Discovery With Quantum Algorithms

Sep 25, 2025, 1:06 PM EDT - 5 months ago

SciSparc Stock Surges As It Launches Initiative To Advance Drug Discovery With Quantum Algorithms

SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery

Sep 25, 2025, 7:05 AM EDT - 5 months ago

SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

Aug 28, 2025, 9:24 AM EDT - 6 months ago

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

Aug 28, 2025, 6:45 AM EDT - 6 months ago

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Aug 7, 2025, 7:32 AM EDT - 7 months ago

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

Jul 30, 2025, 4:34 PM EDT - 7 months ago

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

Jul 30, 2025, 8:12 AM EDT - 7 months ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

Jul 22, 2025, 7:32 AM EDT - 7 months ago

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

SciSparc Announces 1-for-21 Reverse Share Split

Jun 24, 2025, 5:03 PM EDT - 8 months ago

SciSparc Announces 1-for-21 Reverse Share Split

SciSparc Announces Publication of Japanese Patent Application

May 27, 2025, 7:32 AM EDT - 9 months ago

SciSparc Announces Publication of Japanese Patent Application

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Apr 25, 2025, 7:59 AM EDT - 10 months ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

CMND

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

Mar 3, 2025, 8:25 AM EST - 1 year ago

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

Feb 27, 2025, 8:45 AM EST - 1 year ago

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

Feb 18, 2025, 7:17 AM EST - 1 year ago

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

Feb 4, 2025, 9:00 AM EST - 1 year ago

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Jan 15, 2025, 7:34 AM EST - 1 year ago

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

Jan 13, 2025, 8:41 AM EST - 1 year ago

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Jan 7, 2025, 7:25 AM EST - 1 year ago

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

Jan 6, 2025, 11:04 AM EST - 1 year ago

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Jan 6, 2025, 7:50 AM EST - 1 year ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

Dec 31, 2024, 9:24 AM EST - 1 year ago

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

S&P 500 Edges Lower, SciSparc Shares Surge

Dec 26, 2024, 2:36 PM EST - 1 year ago

S&P 500 Edges Lower, SciSparc Shares Surge

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

Dec 26, 2024, 6:46 AM EST - 1 year ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

Dec 16, 2024, 7:40 AM EST - 1 year ago

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

Sep 30, 2024, 9:25 AM EDT - 1 year ago

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

Sep 26, 2024, 9:05 AM EDT - 1 year ago

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 23, 2024, 8:17 AM EDT - 1 year ago

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 18, 2024, 4:09 PM EDT - 1 year ago

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

BillionerOfKing
BillionerOfKing Feb. 23 at 7:07 PM
$SPRC Current Stock Price: $0.53
0 · Reply
LetsWinSD
LetsWinSD Feb. 20 at 7:53 PM
$SPRC not surprised if they do another R/S. Best stock to short. Down 3 - 10% everyday.
0 · Reply
DARKDREAMER
DARKDREAMER Feb. 20 at 7:25 PM
$SPRC I’m watching you
0 · Reply
LetsWinSD
LetsWinSD Feb. 20 at 6:44 PM
$SPRC a constant lower lows. A step down to 0 and delist already. What a POS! Only 2 employees at #SPRC, what a total scam! A bunch of bullshit PR's of patent this and patent that but no actual products.
0 · Reply
LetsWinSD
LetsWinSD Feb. 19 at 6:08 PM
$SPRC TRASH!!! They have been silent and letting retailers bleed.
0 · Reply
LetsWinSD
LetsWinSD Feb. 18 at 11:42 PM
$SPRC your money will dwindle away if you invest in this. A COMPLETE SCAM COMPANY with no real product and BS PR.
0 · Reply
looking4financialfreedom
looking4financialfreedom Feb. 18 at 2:23 AM
$SPRC come on!!!!! Let’s wake up to this ASK price!!!! This would the biggest, most epic turn around of all time! (For me at least) #shortsqueeze
1 · Reply
MovingFast77
MovingFast77 Feb. 17 at 8:58 PM
$SMX AH run . $SMX and $SPRC both #LOWFLOAT ready for a #shortsqueeze
0 · Reply
MAK98TRADER
MAK98TRADER Feb. 17 at 6:52 PM
$SPRC between how the markets been and the stock itself only a really good PR can save this at this point in time oversold technicals are not playing a role here
0 · Reply
LetsWinSD
LetsWinSD Feb. 17 at 6:51 PM
$SPRC A POS! TRASH! SCAM!
0 · Reply
LetsWinSD
LetsWinSD Feb. 17 at 4:09 PM
$SPRC is cooked!
0 · Reply
N0St0pL0ss
N0St0pL0ss Feb. 13 at 10:25 PM
$SPRC Just a matter of time.
1 · Reply
LetsWinSD
LetsWinSD Feb. 13 at 6:43 PM
$SPRC constant dilution, reverse split,..etc. Their just using this as an ATM from retailers. smh...
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 13 at 10:49 AM
$SPRC RSI: 13.06, MACD: -0.2119 Vol: 0.17, MA20: 0.83, MA50: 1.27 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
MovingFast77
MovingFast77 Feb. 13 at 2:56 AM
$SPRC
0 · Reply
MovingFast77
MovingFast77 Feb. 13 at 2:56 AM
$SPRC #smx
0 · Reply
MovingFast77
MovingFast77 Feb. 13 at 2:56 AM
$SPRC
0 · Reply
MovingFast77
MovingFast77 Feb. 13 at 2:54 AM
$SPRC
0 · Reply
MovingFast77
MovingFast77 Feb. 13 at 2:44 AM
$SPRC $SMX
0 · Reply
LetsWinSD
LetsWinSD Feb. 12 at 6:59 PM
$SPRC POS SCAM!!!
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 12 at 4:14 PM
$SPRC Current Stock Price: $0.61
0 · Reply
MovingFast77
MovingFast77 Feb. 12 at 3:06 PM
$SPRC This is going to explode up and is board will be jumping This is the time to get in This could easily be $6 a share at any moment with its low float just like $SMX did just a couple months ago
0 · Reply